Xinxin Liu

Dr. Xinxin Liu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2022 in Bioengineering
Verified
Journal Article
Open access
PDF file
TWTian-Zuo Wang
Tian-Zuo Wang
XLXinxin Liu
Xinxin Liu
SWSi-Yu Wang
Si-Yu Wang
YLYan Liu
Yan Liu
XPXin-Yang Pan
Xin-Yang Pan
KNKai-hui Nan
Kai-hui Nan
Dry eye disease (DED) is a widespread and frequently reported multifactorial ocular disease that not only causes ocular discomfort but also damages the cornea and conjunctiva. At present, topical administration is the most common treatment modality for DED. Due to the existence of multiple biological barriers, instilled drugs generally exhibit short action times and poor penetration on the ocular surface. To resolve these issues, several advanced drug delivery systems have been proposed. This review discusses new dosage forms of drugs for the treatment of DED in terms of their characteristics and advantages. Innovative formulations that are currently available in the market and under clinical investigation are elaborated. Meanwhile, their deficiencies are discussed. It is envisioned that the flourishing of advanced drug delivery systems will lead to improved management of DED in the near future.